Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib.
10.3779/j.issn.1009-3419.2022.101.39
- Author:
Qing ZHOU
1
;
Shun LU
2
;
Yong LI
3
;
Fujun JIA
4
;
Guanjun LI
5
;
Zhen HONG
6
;
You LU
7
;
Yun FAN
8
;
Jianying ZHOU
9
;
Zhe LIU
10
;
Juan LI
11
;
Yi-Long WU
1
Author Information
1. Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
2. Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
3. Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
4. Department of Psychiatry, Guangdong Mental Health Center, Guangzhou 510120, China.
5. Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
6. Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.
7. Department of Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
8. Department of Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
9. Department of Respiratory Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
10. Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
11. Department of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
- Collective Name:Chinese Thoracic Oncology Group (CTONG);Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup
- Publication Type:Journal Article
- Keywords:
Adverse event;
Anaplastic lymphoma kinase;
Lorlatinib;
Lung neoplasms
- MeSH:
Aminopyridines;
Carcinoma, Non-Small-Cell Lung/pathology*;
China;
Consensus;
Drug Resistance, Neoplasm/genetics*;
Drug-Related Side Effects and Adverse Reactions/drug therapy*;
Humans;
Lactams;
Lactams, Macrocyclic/adverse effects*;
Lung Neoplasms/pathology*;
Protein Kinase Inhibitors/adverse effects*;
Protein-Tyrosine Kinases/genetics*;
Pyrazoles
- From:
Chinese Journal of Lung Cancer
2022;25(8):555-566
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy.
.
